A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Clinical trial NCT02034916 · TERMINATED

Trial details

NCT number: NCT02034916
Sponsor: Pfizer
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms BRCA 1 Gene Mutation BRCA 2 Gene Mutation

Start date: 2013-12-13
Primary completion: 2016-09-01
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.